CL2019000229A1 - Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida. - Google Patents

Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida.

Info

Publication number
CL2019000229A1
CL2019000229A1 CL2019000229A CL2019000229A CL2019000229A1 CL 2019000229 A1 CL2019000229 A1 CL 2019000229A1 CL 2019000229 A CL2019000229 A CL 2019000229A CL 2019000229 A CL2019000229 A CL 2019000229A CL 2019000229 A1 CL2019000229 A1 CL 2019000229A1
Authority
CL
Chile
Prior art keywords
bis
new use
mercaptoethyl isophthalamide
prevention
treatment
Prior art date
Application number
CL2019000229A
Other languages
English (en)
Spanish (es)
Inventor
Boyd Eugene Haley
Ragnar Axel Theodor Klingberg
Original Assignee
Emeramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeramed Ltd filed Critical Emeramed Ltd
Publication of CL2019000229A1 publication Critical patent/CL2019000229A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2019000229A 2016-08-05 2019-01-29 Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida. CL2019000229A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201613535 2016-08-05

Publications (1)

Publication Number Publication Date
CL2019000229A1 true CL2019000229A1 (es) 2019-04-26

Family

ID=60202272

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000229A CL2019000229A1 (es) 2016-08-05 2019-01-29 Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida.

Country Status (31)

Country Link
US (2) US20190240173A1 (enExample)
EP (2) EP3493849B1 (enExample)
JP (1) JP6926192B2 (enExample)
KR (1) KR102538388B1 (enExample)
CN (1) CN109562179A (enExample)
AU (1) AU2017305661B2 (enExample)
BR (1) BR112019002130A2 (enExample)
CL (1) CL2019000229A1 (enExample)
CY (1) CY1125039T1 (enExample)
DK (1) DK3493849T3 (enExample)
EA (1) EA201990443A1 (enExample)
ES (1) ES2907838T3 (enExample)
HR (1) HRP20220252T1 (enExample)
HU (1) HUE057782T2 (enExample)
IL (1) IL264538B2 (enExample)
LT (1) LT3493849T (enExample)
MA (1) MA45855B1 (enExample)
MD (1) MD3493849T2 (enExample)
MX (1) MX387853B (enExample)
MY (1) MY199733A (enExample)
NZ (1) NZ750271A (enExample)
PH (1) PH12019500237A1 (enExample)
PL (1) PL3493849T3 (enExample)
PT (1) PT3493849T (enExample)
RS (1) RS62924B1 (enExample)
SG (1) SG11201900565RA (enExample)
SI (1) SI3493849T1 (enExample)
SM (1) SMT202200109T1 (enExample)
UA (1) UA125394C2 (enExample)
WO (1) WO2018025049A1 (enExample)
ZA (1) ZA201900594B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
RU2528396C2 (ru) 2009-09-28 2014-09-20 Юнивёрсити Оф Кентукки Рисёч Фаундейшн Тиолсодержащие соединения для удаления элементов из загрязненной окружающей среды и способы их применения
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet

Also Published As

Publication number Publication date
CN109562179A (zh) 2019-04-02
WO2018025049A1 (en) 2018-02-08
ZA201900594B (en) 2019-08-28
MY199733A (en) 2023-11-21
EP3493849B1 (en) 2021-12-01
PT3493849T (pt) 2022-02-23
SI3493849T1 (sl) 2022-04-29
CA3032858A1 (en) 2018-02-08
BR112019002130A2 (pt) 2019-05-14
SMT202200109T1 (it) 2022-05-12
US20190240173A1 (en) 2019-08-08
PH12019500237A1 (en) 2019-10-28
KR102538388B1 (ko) 2023-05-30
JP2019524782A (ja) 2019-09-05
IL264538B (en) 2022-10-01
ES2907838T3 (es) 2022-04-26
EA201990443A1 (ru) 2019-07-31
MD3493849T2 (ro) 2022-04-30
AU2017305661A1 (en) 2019-02-14
AU2017305661B2 (en) 2023-05-18
UA125394C2 (uk) 2022-03-02
KR20190035724A (ko) 2019-04-03
DK3493849T3 (en) 2022-03-07
EP3493849A1 (en) 2019-06-12
MA45855B1 (fr) 2022-02-28
CY1125039T1 (el) 2023-03-24
JP6926192B2 (ja) 2021-08-25
NZ750271A (en) 2025-07-25
EP4029497A1 (en) 2022-07-20
MX387853B (es) 2025-03-19
PL3493849T3 (pl) 2022-03-28
LT3493849T (lt) 2022-03-10
MX2019000978A (es) 2019-06-10
HRP20220252T1 (hr) 2022-04-29
RS62924B1 (sr) 2022-03-31
HUE057782T2 (hu) 2022-06-28
US20250325503A1 (en) 2025-10-23
IL264538A (enExample) 2019-03-31
MA45855A (fr) 2021-03-17
SG11201900565RA (en) 2019-02-27
IL264538B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
CL2018000978A1 (es) Macrociclos peptídicos contra acinetobacter baumannii
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
DK3328843T3 (da) 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
DOP2017000178A (es) Inhibidores selectivos de bace1
MX2017009449A (es) Inhibidor jak.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2021000196A1 (es) Método de tratamiento de la epilepsia
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2016016534A (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2019000229A1 (es) Nuevo uso de n,n-bis-2-mercaptoetil isoftalamida.
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
GB2543709A (en) Pharmaceutical agent